Clinical Trial for Ripretinib
Studies have shown that if you have GIST with mutations in KIT exons 11 and 17/18, ripretinib may be a better option for second-line treatment than the standard sunitinib.
Studies have shown that if you have GIST with mutations in KIT exons 11 and 17/18, ripretinib may be a better option for second-line treatment than the standard sunitinib.
Every Wednesday in 2024 will be dedicated to learning about the clinical trial process and to highlighting the groundbreaking clinical trials focused on gastrointestinal stromal tumors (GIST). We understand the importance of staying informed [...]
Each member has a unique story, but all reflect the intrinsic courage of one facing the challenge of GIST. Simon Yeung shares his story. #thrivingtogether
Every Wednesday in 2024 will be dedicated to learning about the clinical trial process and to highlighting the groundbreaking clinical trials focused on gastrointestinal stromal tumors (GIST). We understand the importance of staying informed [...]
Each member has a unique story, but all reflect the intrinsic courage of one facing the challenge of GIST. Simon Yeung shares his story. #thrivingtogether
We are thrilled to announce a new initiative aimed at bringing you the latest and most relevant information about ongoing clinical trials: "Clinical Trials Wednesday". Starting in January, every Wednesday will be dedicated learning [...]
Australian liaison Donncha Lynch didn’t know much about GIST or The Life Raft Group yet, but he was determined to learn all he could about GIST.
Thriving Together also means impacting GIST research for our patient community. The LRG contributes and collaborates in the research arena in many ways.
This fall two GIST advocates answered the call to fundraise and rallied their 'crews' - designing and hosting incredibly successful fundraisers.
In 2022, our theme, “It’s Time to Tell the Stories,” marked a significant milestone as we celebrated 20 years of non-profit service. See our 2022 Annual Report.